Search Results

Halberd Corporation’s Traumatic Brain Injury mitigating nasal spray testing protocols at Mississippi State University were approved by the Institutional Animal Care and Use Committee.

The University of Cincinnati Cancer Center inaugurated its state-of-the-art Blood Cancer Healing Center, revolutionizing blood cancer care in the United States.

QT Imaging Holdings, Inc. is honored to partner with University of Oklahoma and OU Health Stephenson Cancer Center to advance and scale innovative research in medical imaging and to improve precision in cancer detection and treatment.

Halberd Corporation is in talks with Mississippi State University to extend its original six-month research arrangement by an additional two years, encompassing yet-to-be defined projects.

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the University of Nebraska Medical Center (UNMC) is now enrolling patients with Locally Advanced Pancreatic Cancer (LAPC) in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial.

Curiox Biosystems is pleased to announce the establishment of the Curiox Innovation Center for the Curiox C-FREE™ Pluto LT System at the Human Immune Monitoring Center (HIMC) at Stanford University.

Halberd Corporation’s Traumatic Brain Injury mitigation research on Halberd’s patent-pending nasal spray continues at Mississippi State University.